Hetero Healthcare Ltd starts supply of generic Remdesivir

By: |
Updated: Jul 15, 2020 12:45 PM

Covifor is the first generic brand of Remdesivir, which is meant for treatment of COVID-19 patients that are adults and children, hospitalised with severe symptoms of the disease.

COVID-19, Hetero Healthcare Ltd,  Covifor, Remdesivir injection, Remdesivir, COVID-19 patients, Dr Reddy's Laboratories Ltd, USFDAThe drug is available in 100 mg vial (Injectable). (Representational image)

Hetero Healthcare Ltd is supplying 60,000 vials of Covifor, generic version of Remdesivir injection in the country from July 13 to 20, the company website said.

Covifor is the first generic brand of Remdesivir, which is meant for treatment of COVID-19 patients that are adults and children, hospitalised with severe symptoms of the disease.

The drug is available in 100 mg vial (Injectable). It needs to be administered intravenously in a hospital, critical care setting, under the supervision of a registered medical practitioner.

Out of 60,000 vials, Maharashtra, which has the highest number of COVID-19 cases in the country will get 12,500 followed by Delhi and Telangana with 10,000 and 9,000 respectively.

Watch video: Indian Railways unveils world’s 1st safer train coaches for post Covid-19 travel; top features!

According to the website, Tamil Nadu, Gujarat, Andhra Pradesh and Karnataka will get 7500, 6000, 2000 and 3000 respectively while the rest of the country will get 10,000 injections.

The company has supplied the drug to as many as 166 hospitals in Maharashtra and 53 in the national capital. When it comes to Telangana , Hetero supplied 14,502 vials, the information available at 11 AM on the site on Wednesday said.

Remdesivir is the only drug approved by the United States Food and Drug Administration (USFDA) for Emergency Use Authorisation (EUA) treatment of adult and paediatric patients hospitalised with suspected or laboratory confirmed COVID-19 infection.

Meanwhile, Dr Reddy’s Laboratories Ltd, which also has a non-exclusive licensing agreement with Gilead Sciences Inc to register, manufacture and sell the investigational drug, Remdesivir in 127 countries including India is yet to get a nod from the DCGI to start making the drug in the country, sources said.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Coronavirus and road to recovery: Time is the only best medicine we have
2Delhi records 4,116 COVID-19 cases, highest single-day spike in 35 days
3Delhi airport starts COVID-19 testing for international departures: Genestrings